Table 1.
Groups of mice used in the studies.
Figure 1.
Comparison of brown adipose tissue (BAT) 18F-FDG uptake in the normal, obese, and diabetes mellitus (DM) mice and their response to BRL37344 intervention.
A: Typical 18F-FDG microPET images of normal, obese, and DM mice after cold stimulation by steping on ice for 1 h. Arrows showed that the interscapular BAT uptake of 18F-FDG was decreased in the obese and DM mice. B: Semi-quantitative analysis of BAT-to-liver ratio (BAT/L) of 18F-FDG uptake showed that the BAT/L was significanly lower in the obese mice (P = 0.036) and further decreased in the DM mice (P<0.001). C: Two-week BRL37344 intervetion (three times per week) significantly increased the BAT/L in the obese mice (P = 0.010) and DM mice (P = 0.004) compared to the corresponding controls. D: Single-dose BRL37344 intervention also significantly increased the BAT/L in the normal mice (P = 0.002).
Table 2.
The 1-h biodistribution of 18F-FDG in normal mouse with and without BRL37344 intervention.
Table 3.
Comparison of serum levels of glucose, total cholesterol, and low-density lipoprotein-cholesterol in the control, obese, and DM mice.
Figure 2.
Comparison of the changes of body weight in the obese mice with and without BRL37344 treatment.
Significant weight loss was observed after two weeks of BRL37344 treatment (* P = 0.001).
Figure 3.
Comparison of brown adipose tissue (BAT) 18F-FDG uptake in the normal, obese, and diabetes mellitus (DM) mice underwent levothyroxine treatment.
A, B, and C: Typical microPET images, with the arrows showing the interscapular BAT uptake of 18F-FDG in the mice. D: Semi-quantitative analysis of BAT-to-liver uptake ratio (BAT/L) showed that after two-week levothyroxine treatment, the BAT/L in the normal and obese mice were significantly increased compared to the corresponding controls (P = 0.025 and 0.013, respectively), whereas the increase of BAT/L in the DM mice was not significant (P = 0.450).